VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
Recruitment status was: Active, not recruiting
|End-stage Heart Failure Cardiomyopathies||Device: VentrAssistTM Left Ventricular Assist Device||Phase 3|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Evaluation of the VentrAssistTM Left Ventricular Assist Device as a Bridge to Cardiac Transplantation - Pivotal Trial|
- Survival to cardiac transplantation or to 180 days post implantation and listed for cardiac transplantation in categories UNOS 1A or 1B.
- Quality of life
- Functional status
- Neurocognitive function
|Study Start Date:||June 2007|
|Estimated Study Completion Date:||June 2010|
LVADs are efficacious in improving survival and functional status when used as a bridge to transplantation. The purpose of this study is to evaluate the safety and effectiveness of the VentrAssist LVAD in providing circulatory support in individuals who are awaiting heart transplants.
The VentrAssist LVAD is a centrifugal flow pump. Its small size and mechanical simplicity offers benefits not available with currently approved LVADs, including facilitating a more limited implantation procedure, which could reduce surgical morbidity and mortality.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00483197
Show 29 Study Locations